Schizophrenia typically starts gradually, with subtle changes in thinking, mood, and behavior that can appear months or even years before a full psychotic episode. Most people experience their first episode between the ages of 20 and 29, though the buildup often begins in late adolescence. Understanding what this early phase looks like, and what’s happening in the brain during it, can make a real difference in how quickly someone gets help.
The Prodromal Phase: What Changes First
Before hallucinations or delusions ever appear, most people go through a “prodromal” phase of milder, less obvious changes. This period can last weeks, months, or sometimes over a year. The changes often look like ordinary adolescent struggles or depression, which is part of why they’re so easy to miss.
The earliest shifts tend to be social and emotional. A person may pull away from friends and family, lose interest in activities they used to enjoy, or stop keeping up with hygiene and grooming. Their performance at school or work often drops noticeably. Sleep patterns may change. They may seem flat or emotionally blunted, reacting to things in ways that seem off, or barely reacting at all.
Thinking and communication also shift during this phase. Speech might become vague, hard to follow, or unusually elaborate. Some people develop odd beliefs or “magical thinking,” like believing they can influence events with their thoughts. Others report unusual perceptual experiences that fall short of full hallucinations, such as feeling like familiar things look different or sounds seem distorted. Anxiety, depression, irritability, and mood swings are common, and some people experience obsessive or repetitive thoughts. A persistent, hard-to-explain loss of energy and motivation is one of the most frequently reported early symptoms.
Cognitive problems are often among the first measurable changes. Memory, attention, and concentration all tend to decline. Verbal memory, the ability to learn and recall spoken or written information after a delay, is the single most consistent predictor of who will go on to develop a psychotic episode. Processing speed and the ability to read social cues may also slip. These deficits can be subtle enough that they’re only obvious in hindsight.
What’s Happening in the Brain
During adolescence, the brain goes through a natural process called synaptic pruning: trimming away unused neural connections to make the remaining ones more efficient. In people who develop schizophrenia, this process appears to go too far. Post-mortem studies show fewer dendritic spines (the tiny connection points between brain cells) in the brains of people with schizophrenia, suggesting either excessive pruning, insufficient formation of new connections, or both.
One of the strongest genetic findings in schizophrenia research links the condition to a protein called C4A, part of the immune system. Risk-associated gene variants lead to higher levels of C4A, which tags neural connections for removal. The brain’s immune cells then engulf those tagged connections more aggressively. Lab studies have shown this process is measurably more aggressive when cells come from people with schizophrenia, and the degree of overactivity correlates with how much C4A is being produced. Because pruning is concentrated in the prefrontal cortex during adolescence, that’s when the damage becomes apparent.
Brain imaging tells a similar story. People in the early stages of schizophrenia show accelerated loss of gray matter in the frontal and temporal regions of the brain, the areas responsible for planning, decision-making, language, and memory. The fluid-filled spaces inside the brain (ventricles) also enlarge progressively. These structural changes are visible on MRI scans even during first episodes and continue over time.
The Dopamine Connection
The brain’s dopamine system plays a central role in how symptoms emerge. The current understanding is that schizophrenia involves a dopamine imbalance running in two directions simultaneously. In deeper, subcortical brain regions, dopamine signaling becomes overactive. This excess drives the “positive” symptoms: hallucinations, delusions, and paranoia. At the same time, dopamine activity in the prefrontal cortex drops too low, contributing to the “negative” symptoms like flat emotions, lack of motivation, and difficulty with speech.
Dopamine doesn’t act alone. Disruptions in glutamate signaling, particularly through a specific receptor type in the prefrontal cortex and hippocampus, can trigger abnormal dopamine release in subcortical areas. This creates a feedback loop: cortical dysfunction feeds subcortical overactivity, which reinforces the cortical problems. Other chemical messenger systems, including those involving serotonin and GABA, are also involved.
Who Gets It and When
Genetics account for roughly 79% of the risk for developing schizophrenia, based on nationwide twin studies. Among identical twins, if one has schizophrenia, the other develops it about 33% of the time. Among fraternal twins, that rate drops to 7%. The fact that identical twins, who share all their DNA, are concordant only a third of the time makes it clear that genes alone don’t determine the outcome.
Men tend to develop schizophrenia 3 to 4 years earlier than women. In men, the peak incidence falls between ages 20 and 29, and prevalence is higher for those under 40. Women show two separate peaks: one between 20 and 39, and a second around perimenopause. Estrogen is thought to have a protective effect, which may explain both the later onset and the second peak when estrogen levels decline.
Environmental Triggers That Raise the Risk
Several environmental factors can push a genetically vulnerable person toward developing schizophrenia. Complications before and during birth, including low birthweight, premature labor, and oxygen deprivation during delivery, are associated with higher risk later in life.
Drug use is one of the most significant modifiable risk factors. Cannabis, cocaine, LSD, and amphetamines all increase the risk of developing schizophrenia or a related psychotic illness. The link with cannabis is especially well-studied: teenagers and young adults who use it regularly are more likely to develop schizophrenia in later adulthood, with stronger forms of cannabis carrying higher risk. For someone already in a prodromal phase, substance use can accelerate the transition to a full psychotic episode.
From Early Symptoms to a Diagnosis
A formal diagnosis of schizophrenia requires at least two core symptoms present for a significant portion of a one-month period: delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, or negative symptoms like diminished emotional expression and lack of motivation. At least one of the symptoms must be delusions, hallucinations, or disorganized speech. Signs of the disturbance, including prodromal or residual symptoms, must persist for at least six months total. There also has to be a clear decline in functioning at work, in relationships, or in self-care compared to before the illness started.
The diagnosis also requires ruling out mood disorders with psychotic features, substance-induced psychosis, and other medical conditions that can mimic schizophrenia.
Why Early Treatment Matters
The time between the appearance of psychotic symptoms and the start of treatment, known as the duration of untreated psychosis, has a significant impact on long-term outcomes. Each doubling of this untreated period predicts 8 to 12% more severe symptoms and 3 to 8% worse functional outcomes down the line. A person who goes untreated for four weeks has over 20% more severe symptoms at follow-up compared to someone treated within the first week.
Longer delays before treatment are also associated with a lower chance of remission, more severe negative symptoms at first presentation, and higher rates of self-harm. The prodromal phase, while not yet psychosis, represents a window where monitoring and support can potentially shorten that gap between when symptoms cross into psychosis and when treatment begins.